{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T23:01:04Z","timestamp":1781737264018,"version":"3.54.5"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2019,2,28]],"date-time":"2019-02-28T00:00:00Z","timestamp":1551312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,2,28]],"date-time":"2019-02-28T00:00:00Z","timestamp":1551312000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Indian J Pediatr"],"published-print":{"date-parts":[[2019,8,1]]},"DOI":"10.1007\/s12098-019-02882-y","type":"journal-article","created":{"date-parts":[[2019,2,28]],"date-time":"2019-02-28T05:10:16Z","timestamp":1551330616000},"page":"732-739","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Monitoring Treatment of Childhood Tuberculosis and the Role of Therapeutic Drug Monitoring"],"prefix":"10.1007","volume":"86","author":[{"given":"Andrea T.","family":"Cruz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6218-6697","authenticated-orcid":false,"given":"Jeffrey R.","family":"Starke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,2,28]]},"reference":[{"key":"2882_CR1","unstructured":"World Health Organization. Global Tuberculosis Report: 2018. Geneva: World Health Organization; 2018. Available online at http:\/\/apps.who.int\/iris\/bitstream\/handle\/10665\/274453\/9789241565646-eng.pdf?ua=1. Accessed 25 November 2018."},{"key":"2882_CR2","doi-asserted-by":"publisher","first-page":"e00008","DOI":"10.1128\/AAC.00008-18","volume":"62","author":"Y Horita","year":"2018","unstructured":"Horita Y, Alsultan A, Kwara A, et al. Evaluation of the adequacy of WHO revised dosages of the first-line antituberculosis drugs in children with tuberculosis using population pharmacokinetic modeling and simulations. Antimicrob Agents Chemother. 2018;62:e00008\u201318.","journal-title":"Antimicrob Agents Chemother"},{"key":"2882_CR3","doi-asserted-by":"publisher","first-page":"2171","DOI":"10.1128\/AAC.02600-15","volume":"60","author":"A Bekker","year":"2016","unstructured":"Bekker A, Schaaf HS, Draper HR, et al. Pharmacokinetics of rifampin, isoniazid, pyrazinamide, and ethambutol in infants dosed according to revised WHO-recommended treatment guidelines. Antimicrob Agents Chemother. 2016;60:2171\u20139.","journal-title":"Antimicrob Agents Chemother"},{"key":"2882_CR4","doi-asserted-by":"publisher","first-page":"e898","DOI":"10.1016\/S2214-109X(17)30289-9","volume":"5","author":"PJ Dodd","year":"2017","unstructured":"Dodd PJ, Yuen CM, Sismanidi C, et al. The global burden of tuberculosis mortality in children: a mathematical modelling study. Lancet Glob Health. 2017;5:e898\u2013906.","journal-title":"Lancet Glob Health"},{"key":"2882_CR5","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1097\/INF.0000000000001532","volume":"36","author":"Y Li","year":"2017","unstructured":"Li Y, Zhu Y, Zhong Q, et al. Serious adverse reactions from antituberculosis drugs among 599 children hospitalized for tuberculosis. Pediatr Infect Dis J. 2017;36:720\u20135.","journal-title":"Pediatr Infect Dis J"},{"key":"2882_CR6","doi-asserted-by":"publisher","DOI":"10.4081\/pr.2011.e16","volume":"3","author":"PR Donald","year":"2011","unstructured":"Donald PR. Antituberculosis drug-induced hepatotoxicity in children. Pediatr Rep. 2011;3:e16.","journal-title":"Pediatr Rep"},{"key":"2882_CR7","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1093\/jpids\/pit089","volume":"3","author":"SH Chang","year":"2014","unstructured":"Chang SH, Nahid P, Eitzman SR. Hepatotoxicity in children receiving isoniazid therapy for tuberculosis infection. J Pediatr Infect Dis Soc. 2014;3:221\u20137.","journal-title":"J Pediatr Infect Dis Soc."},{"key":"2882_CR8","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1542\/pir.31-1-13","volume":"31","author":"AT Cruz","year":"2010","unstructured":"Cruz AT, Starke JR. Pediatric tuberculosis. Pediatr Rev. 2010;31:13\u201325.","journal-title":"Pediatr Rev"},{"key":"2882_CR9","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1097\/INF.0000000000002135","volume":"37","author":"AT Cruz","year":"2018","unstructured":"Cruz AT, Garcia-Prats AJ, Furin J, Seddon JA. Treatment of multidrug-resistant tuberculosis infection in children. Pediatr Infect Dis J. 2018;37:1061\u20134.","journal-title":"Pediatr Infect Dis J"},{"key":"2882_CR10","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1097\/00006454-199708000-00006","volume":"16","author":"I Sanchez-Albisua","year":"1997","unstructured":"Sanchez-Albisua I, Vidal ML, Joya-Verde G, et al. Tolerance of pyrazinamide in short course chemotherapy for pulmonary tuberculosis in children. Pediatr Infect Dis J. 1997;16:760\u20133.","journal-title":"Pediatr Infect Dis J"},{"key":"2882_CR11","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1111\/apa.12908","volume":"104","author":"S Leeb","year":"2015","unstructured":"Leeb S, Buxbaum C, Fischler B. Elevated transaminases are common in children on prophylactic treatment for tuberculosis. Acta Paediatr. 2015;104:479\u201384.","journal-title":"Acta Paediatr"},{"key":"2882_CR12","first-page":"1318","volume":"10","author":"PR Donald","year":"2006","unstructured":"Donald PR, Maher D, Maritz JS, Qazi S. Ethambutol dosage for the treatment of children: literature review and recommendations. Int J Tuberc Lung Dis. 2006;10:1318\u201330.","journal-title":"Int J Tuberc Lung Dis"},{"key":"2882_CR13","unstructured":"World Health Organization. Ethambutol efficacy and toxicity: literature review and recommendations for daily and intermittent dosage in children. Geneva: 2006. Available online at: http:\/\/apps.who.int\/iris\/bitstream\/handle\/10665\/69366\/WHO_HTM_TB_2006.365_eng.pdf;jsessionid=0524004F476B8A6010AF93059C007BCE?sequence=1. Accessed 24 October 2018."},{"key":"2882_CR14","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/j.tube.2015.02.037","volume":"95","author":"S Thee","year":"2015","unstructured":"Thee S, Garcia-Prats AJ, Donald PR, et al. Fluoroquinolones for the treatment of tuberculosis in children. Tuberculosis (Edinb). 2015;95:229\u201345.","journal-title":"Tuberculosis (Edinb)"},{"key":"2882_CR15","doi-asserted-by":"publisher","first-page":"228","DOI":"10.4274\/jcrpe.1867","volume":"7","author":"S Elmaogullari","year":"2015","unstructured":"Elmaogullari S, Tepe D, U\u00e7akt\u00fcrk SA, et al. Prevalence of dyslipidemia and associated factors in obese children and adolescents. J Clin Res Pediatr Endocrinol. 2015;7:228\u201334.","journal-title":"J Clin Res Pediatr Endocrinol"},{"key":"2882_CR16","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1093\/cid\/ciw694","volume":"64","author":"DM Lewinsohn","year":"2016","unstructured":"Lewinsohn DM, Leonard MK, LoBue PA, et al. Official American Thoracic Society \/ Infectious Diseases Society of America \/ Centers for Disease Control and Prevention clinical practice guidelines: diagnosis of tuberculosis in adults and children. Clin Infect Dis. 2016;64:e1\u201333.","journal-title":"Clin Infect Dis"},{"key":"2882_CR17","first-page":"14","volume":"10","author":"M Gopi","year":"2016","unstructured":"Gopi M, Seshadri MS. Biphasic effect of rifampicin on bilirubin \u2013 a case report. J Clin Diagn Res. 2016;10:14\u20135.","journal-title":"J Clin Diagn Res"},{"key":"2882_CR18","doi-asserted-by":"crossref","unstructured":"Holla SK, Achappa B, ManibettuRaguram P, et al. Isoniazid-induced pure red cell aplasia. BMJ Case Rep. 2018;.pii:bcr-2018-226134.","DOI":"10.1136\/bcr-2018-226134"},{"key":"2882_CR19","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1378\/chest.96.1.202","volume":"96","author":"CH Lee","year":"1989","unstructured":"Lee CH, Lee CJ. Thrombocytopenia \u2013 a rare but potentially serious side effect of initial daily and interrupted use of rifampicin. Chest. 1989;96:202\u20133.","journal-title":"Chest"},{"key":"2882_CR20","first-page":"320","volume":"66","author":"JA Seddon","year":"2013","unstructured":"Seddon JA, Thee S, Jacobs K, et al. Hearing loss in children treated for multidrug-resistant tuberculosis. J Inf Secur. 2013;66:320\u20139.","journal-title":"J Inf Secur"},{"key":"2882_CR21","doi-asserted-by":"publisher","first-page":"1806","DOI":"10.3201\/eid2410.180459","volume":"24","author":"RS Garfein","year":"2018","unstructured":"Garfein RS, Liu L, Cuevas-Mota J, et al. Tuberculosis treatment monitoring by video directly observed therapy in 5 health districts, California, USA. Emerg Infect Dis. 2018;24:1806\u201315.","journal-title":"Emerg Infect Dis"},{"key":"2882_CR22","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1093\/jac\/dku376","volume":"70","author":"HE Reynolds","year":"2015","unstructured":"Reynolds HE, Chrdle A, Egan D, et al. Effect of intermittent rifampicin on the pharmacokinetics and safety of raltegravir. J Antimicrob Chemother. 2015;70:550\u20134.","journal-title":"J Antimicrob Chemother"},{"key":"2882_CR23","unstructured":"World Health Organization. Management of Tuberculosis and HIV Coinfection: Clinical Protocol for the WHO European Region. Available at: http:\/\/www.euro.who.int\/__data\/assets\/pdf_file\/0004\/78124\/E90840_Chapter_4.pdf. Accessed 25 November 2018."},{"key":"2882_CR24","doi-asserted-by":"crossref","first-page":"e01701","DOI":"10.1128\/AAC.01701-16","volume":"61","author":"S Antwi","year":"2017","unstructured":"Antwi S, Yang H, Enimil A, et al. Pharmacokinetics of the first-line antituberculosis drugs in Ghanaian children with tuberculosis with or without HIV coinfection. Antimicrob Agents Chemother. 2017;61:e01701\u201316.","journal-title":"Antimicrob Agents Chemother"},{"key":"2882_CR25","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1093\/jpids\/piv035","volume":"5","author":"A Kwara","year":"2015","unstructured":"Kwara A, Enimil A, Gillani FS, et al. Pharmacokinetics of first-line antituberculosis drugs using WHO revised dosage in children with tuberculosis with and without HIV coinfection. J Pediatr Infect Dis Soc. 2015;5:356\u201365.","journal-title":"J Pediatr Infect Dis Soc"},{"key":"2882_CR26","doi-asserted-by":"crossref","unstructured":"American Academy of Pediatrics. Tuberculosis. In: Kimberlin DW, Brady MT, Jackson MA, Long SS, editors. Red Book: 2018 Report of the Committee on Infectious Diseases. 31st Ed. Itasca, IL: American Academy of Pediatrics; 2018:p.829\u2013853.","DOI":"10.1542\/9781610021470-part03-tuberculosis"},{"key":"2882_CR27","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1007\/s40265-014-0222-8","volume":"74","author":"A Alsultan","year":"2014","unstructured":"Alsultan A, Peloquin CA. Therapeutic drug monitoring in the treatment of tuberculosis: an update. Drugs. 2014;74:839\u201354.","journal-title":"Drugs"},{"key":"2882_CR28","doi-asserted-by":"publisher","unstructured":"Peloquin C. The role of therapeutic drug monitoring in mycobacterial infections. Microbiol Spectr. 2017;5. https:\/\/doi.org\/10.1128\/microbiolspec.TNM17-0029-2016.","DOI":"10.1128\/microbiolspec.TNM17-0029-2016"},{"key":"2882_CR29","doi-asserted-by":"publisher","first-page":"5560","DOI":"10.1128\/AAC.05429-11","volume":"55","author":"S Thee","year":"2011","unstructured":"Thee S, Seddon JA, Donald PR, et al. Pharmacokinetics of isoniazid, rifampin, and pyrazinamide in children younger than 2 years of age with tuberculosis: evidence for implementation of revised World Health Organization recommendations. Antimicrob Agents Chemother. 2011;55:5560\u20137.","journal-title":"Antimicrob Agents Chemother"},{"key":"2882_CR30","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1016\/j.tube.2010.07.002","volume":"90","author":"PR Donald","year":"2010","unstructured":"Donald PR. Cerebrospinal fluid concentrations of antituberculosis agents in adults and children. Tuberculosis (Edinb). 2010;90:279\u201392.","journal-title":"Tuberculosis (Edinb)."},{"key":"2882_CR31","doi-asserted-by":"publisher","first-page":"e147","DOI":"10.1093\/cid\/ciw376","volume":"63","author":"P Nahid","year":"2016","unstructured":"Nahid P, Dorman SE, Alipaneh N, et al. Official American Thoracic Society \/ Centers for Disease Control and Prevention \/ Infectious Diseases Society of America clinical practice guidelines: treatment of drug-susceptible tuberculosis. Clin Infect Dis. 2016;63:e147\u201395.","journal-title":"Clin Infect Dis"},{"key":"2882_CR32","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1111\/joim.12780","volume":"284","author":"C Lange","year":"2018","unstructured":"Lange C, Alghamdi WA, Al-Shaer MH, et al. Perspectives for personalized therapy for patients with multidrug-resistant tuberculosis. J Int Med. 2018;284:163\u201388.","journal-title":"J Int Med"}],"container-title":["The Indian Journal of Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12098-019-02882-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12098-019-02882-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12098-019-02882-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,29]],"date-time":"2022-07-29T11:35:59Z","timestamp":1659094559000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12098-019-02882-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2,28]]},"references-count":32,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2019,8,1]]}},"alternative-id":["2882"],"URL":"https:\/\/doi.org\/10.1007\/s12098-019-02882-y","relation":{},"ISSN":["0019-5456","0973-7693"],"issn-type":[{"value":"0019-5456","type":"print"},{"value":"0973-7693","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,2,28]]},"assertion":[{"value":"4 December 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 January 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 February 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"Dr. Starke is a member of a Data Safety Monitoring Board for the pediatric studies of Delamanid for Otsuka Pharmaceuticals. There is no overlap with-this manuscript. Dr. Cruz has no Conflict of Interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"None.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Source of Funding"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}